H igh density lipoprotein inhibits LDL modification 1, 2 and abolishes the induction of monocyte chemotactic protein-1 (MCP-1) in arterial wall cells, thus preventing monocyte transmigration. 3 HDL-associated enzymes possess antiatherogenic properties that may be due, in part, to their interaction with oxidized LDL. Paraoxonase-1 (PON1, EC 3.1.8.1) is 1 of several enzymes associated with HDL. PON1 is a calcium-dependent ester hydrolase that is tightly associated with apoA-I in HDL. 4 Purified PON1 prevents LDL oxidation in vitro, 5 and treatment of mildly oxidized LDL (MM-LDL) with purified PON1 significantly reduces the ability of MM-LDL to induce monocyte-endothelial interactions. 6 Human epidemiological studies have shown that polymorphisms of the human PON1 gene are correlated with coronary artery disease, indicating a genetic association between PON1 and coronary artery disease. 7, 8 Mackness et al 9 showed that alloenzymes of PON1 determine the effectiveness of HDL in protecting LDL from lipid peroxidation. Mice lacking serum PON1 exhibit increased LDL oxidation in vivo and are more susceptible to atherosclerosis than are wild-type mice. 10, 11 
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Two other members of the paraoxonase (PON) gene family, termed PON2 and PON3, have been identified. 12 It is not known whether PON2 and PON3 play a role similar to PON1 in the regulation of atherosclerosis. All 3 PON genes are located adjacent to each other on chromosome 7 in humans and on chromosome 6 in mice and seem to be a result of gene duplication. The 3 PON genes share Ϸ65% similarity at the amino acid level. Although the physiological roles of the corresponding gene products are still unknown, the ability to hydrolyze paraoxon (PON activity) and phenylacetate (arylesterase activity) is routinely used for measuring PON1 activity in vitro and in serum samples. To date, only PON1 has been purified and characterized from human sources, and PON and/or arylesterase activities have not been reported for human PON2 and human PON3. PON1 is expressed primarily in the liver. PON2, on the other hand, is expressed widely in a number of tissues, including, brain, liver, kidney, and testis, and may have multiple mRNA forms. 13 PON3 expression in human tissues has not been reported. Missense variations of PON2 have also been reported, and significant associations were observed between PON2 polymorphisms, variation in plasma lipoprotein levels, and risk for heart disease. 14 -17 To date, there are no reports on polymorphisms in the PON3 gene.
In the present study, we report the cloning and characterization of human PON3 from HepG2 cells. PON3 is an Ϸ40-kDa protein primarily synthesized in the liver and is associated with HDL fractions of human plasma. PON3 not only prevents the formation of MM-LDL but also inhibits MM-LDL-induced monocyte chemotactic activity. Our data suggest that PON3 is similar to PON1 in its association with HDL and the prevention of MM-LDL formation or the inactivation of MM-LDL. However, unlike PON1, PON3 expression is not affected in HepG2 cells by oxidized phospholipids or in the livers of mice by a high-fat diet.
Methods

Materials
Cell culture reagents and oligonucleotides were purchased from GIBCO-BRL. Human tissue blots containing 2 g of poly A ϩ RNA in each lane were from Origene Technologies Inc. L-␣-1-Palmitoyl-2-arachidonoyl-sn-glycero-3-phosphotidylcholine (PAPC) was obtained from Avanti Polar Lipids. Oxidized PAPC (ox-PAPC) was prepared as described previously. 18 Purified PON1 was a generous gift from B.N. La Du (University of Michigan, Ann Arbor). LDL (density 1.019 to 1.063 g/mL) and HDL (density 1.063 to 1.21 g/mL) were isolated according to the protocol described by Havel et al 19 from the plasma of normal volunteers after obtaining informed consent according to the Human Research Subject Protection Committee at the University of California, Los Angeles (UCLA). LDL and HDL had endotoxin levels Ͻ20 pg/mL.
Cell Culture
HepG2 cells were cultured on 0.1% gelatin-coated plates in EMEM medium containing 10% FBS, 1% nonessential amino acids, and 1 mmol/L sodium pyruvate. HeLa Tet On cells (Clontech) were grown in DMEM high glucose containing 10% tetracycline-free FBS. Human aortic endothelial cells (HAECs) were isolated and cultured as described previously. 3 Cells (2ϫ10 5 cells/cm 2 ) were allowed to grow, forming a complete monolayer of confluent HAECS in 2 days. HAECS were used at passage levels 4 to 6. Monocytes were isolated by a modification of the Recalde method, as previously described by Fogelman et al, 20 from the blood of normal volunteers after obtaining written consent under a protocol approved by the Human Research Subject Protection Committee at UCLA. The 293 cells were cultured in DMEM high glucose containing 10% FBS.
Cloning of Human PON1 and PON3 From HepG2 Cells
On the basis of the available sequence information in the NCBI databases, specific primers were designed to amplify the complete coding sequences of PON1 and PON3. The PON1-and PON3-specific primers along with HepG2 cell total RNA (1 g) were subjected to reverse transcriptase (RT)-polymerase chain reaction (PCR) by use of the Access RT-PCR system kit from Promega. The upper and lower primers for human PON1 were 5Ј ATTAGTCGAC-GACCATGGCGAAGCTGATT 3Ј and 5Ј ATAGTTTAGCGGC-CGCTTAGAGCTCACAGTAAAGA 3Ј, respectively, and the upper and lower primers for human PON3 were 5Ј GATTAGTCGACCAT-GGGGAAGCTCGTGGCGCT 3Ј and 5Ј ATAGTTTAGCGGC-CGCTTAGAGCTCACAGTAC 3Ј, respectively. In each set of primers, the upper primers contained a SalI restriction site on the 5Јend, and the lower primer had a NotI restriction site on the 3Јend. After RT-PCR, the products were identified on agarose gel and cloned into the pCR II vector with a TOPO TA cloning kit (Invitrogen). Multiple clones containing the PON1 and PON3 cDNA were sequenced at the UCLA sequencing core facility. The sequences were aligned with PON1 and PON3 sequences available in the National Center for Biotechnology Information databases by using MacVector and Assemblyalign programs. SalI-NotI fragments containing PON1 and PON3 were excised from the TA vectors and cloned into pGex-6p2 (Amersham Pharmacia Biotech). BL21 bacteria were transformed with the resulting glutathione S-transferase (GST) plasmids, and GST fusion proteins were prepared according to the manufacturer's protocol. These GST-PON1 and GST-PON3 fusion proteins were verified by size on polyacrylamide gel. We also cloned the SalI-NotI PON1 and PON3 cDNAs into a plasmid containing tetracycline response element (TRE) to generate pTRE-PON1 and pTRE-PON3, respectively. RT-PCR amplification of mouse PON3 was performed by using mouse PON3 upper primer 5Ј ATCTTGGACCCTCACTGGACTT 3Ј and mouse PON3 lower primer 5Ј ACAGCTTCATGGGGTTAGGGTG 3Ј.
Antibody Generation and Specificity
Peptides CRNHQSSYQTRLNALREVQ (PON1) and CRV-NASQEVEPVEPEN (PON3) were synthesized at the UCLA peptide synthesis core facility. Peptides were chosen on the basis of their hydrophilicity as well as their specificity to the corresponding PON protein. The cysteine residues in the N-terminus of each peptide are not part of the original PON1 and PON3 sequences. They were added to PON1 and PON3 peptides to facilitate conjugation to carrier protein. Two milligrams of each peptide was conjugated to 2 mg of keyhole limpet hemocyanin (KLH) by using the Imject MaleimideActivated KLH kit (Pierce), and the KLH-conjugated peptides were purified according to manufacturer's protocol. Rabbit polyclonal antibodies against PON1-and PON3-conjugated peptides were developed at Cocalico Biologicals. Total lysates (5 g each) from GST-PON1-and GST-PON3-expressing bacteria were used to determine the specificity of PON1 and PON3 antibodies. PON1 antibody recognizes the GST-PON1 protein and not the GST-PON3 protein. Similarly, the PON3 antibody detects the GST-PON3 protein but not the GST-PON1 protein. In immune-depletion experiments, PON1 and PON3 antibodies preincubated with 1 g of PON1-and PON3-specific peptides, respectively, did not detect their corresponding GST fusion protein. Immune-depletion experiments in which the PON1 and PON3 antibodies were preincubated with either the corresponding peptide antigen or GST fusion protein enabled the identification of mammalian and of expressed PON1 and PON3 proteins on Western blots.
Western Analysis
Appropriate protein samples were reduced in ␤-mercaptoethanol, boiled, electrophoresed on 10% SDS-PAGE gels, and electroblotted onto Hybond ECL nitrocellulose membranes by using a semidry transfer apparatus from Bio-Rad. Membranes were blocked with Tris-buffered saline/5% nonfat dry milk for 60 minutes, washed, and incubated with primary and secondary antibodies for 2 hours and 1 hour, respectively. The secondary antibody used was horseradish peroxidase-conjugated anti-rabbit IgG (Amersham). Primary and secondary antibodies were used at 1:1000 and 1:4000 dilutions, respectively. The membranes were washed extensively with Trisbuffered saline/0.1% Tween after secondary antibody incubation and detected by using the ECL Western blotting kit (Amersham) according to the manufacturer's suggested protocol. To determine the presence of PON1 and PON3 in human lipoproteins, equal amounts of HDL and LDL fractions (based on cholesterol content, 1.4 g), isolated by fast-performance liquid chromatography, were resolved on SDS-PAGE. Approximately 0.25 g of purified PON1 and 80 g of concentrated 293 cell culture supernatants were used as positive controls for PON1 and PON3, respectively.
Establishment of HeLa-Tet-PON1 and HeLa-Tet-PON3 Cell Lines
HeLa Tet On cells (Clontech) were cotransfected with either pTRE-PON1 or pTRE-PON3 and pBabe-Puro (puromycin-resistant plasmid) by using Superfect reagent (Qiagen Inc). The day after transfection, the cultures were given medium containing 0.1 g/mL of puromycin. After 10 days, puromycin-resistant clones were isolated, expanded, and tested for doxycycline inducibility. Several isolates of HeLa-Tet-PON1 or HeLa-Tet-PON3 with high doxycycline-inducible expression were pooled and used for the present study. The cells were treated for 2 days with 2 g/mL of doxycycline for induction of PON message and protein. After induction with doxycycline, supernatants from HeLa-Tet-PON1 and HeLa-Tet-PON3 cells were collected and concentrated by using Centricon-10 filters (Millipore). For Western analysis, cells were lysed in a buffer containing 50 mmol/L Tris (pH 7.5), 100 mmol/L NaCl, 5 mmol/L EDTA, 5 mmol/L sodium orthovanadate, 1% Triton X-100, and protease inhibitors.
Northern Analysis
Total RNA from cell cultures was purified by using the RNeasy kit (Qiagen Inc). Ten micrograms of total RNA from HepG2 cells or 2.5 g of total RNA from HeLa Tet On cell lines was subjected to electrophoresis on 1% agarose gel, transferred to Hybond-N membranes (Amersham Pharmacia Biotech), and hybridized with cDNA probes for human PON1, PON3, and GAPDH. Electrophoresis and hybridization protocols have been described previously. 21 
Monocyte Chemotaxis Assay and Lipid Hydroperoxide Measurement
HAECs were plated at 2ϫ10 5 cells/cm 2 and allowed to grow, forming a monolayer of confluent HAECs in 2 days. To study the formation of MM-LDL by HAECs, confluent cultures were preincubated for 2 hours with concentrated supernatants from HeLa-Tet-PON1 and HeLa-Tet-PON3 cells. The cells were washed and further incubated with native LDL (200 g of LDL protein/mL) in medium 199 containing 10% lipoprotein-deficient serum. Fourteen hours later, supernatants were collected and stored until further analysis. For monocyte chemotaxis assay, supernatants were diluted 40-fold and assayed as described previously. 22 The number of migrated monocytes was determined microscopically and expressed as the meanϮSD of 12 standardized high-power fields counted in quadruplicate wells. For lipid hydroperoxide content, lipids in supernatants from HAECs were extracted with chloroform-methanol, and hydroperoxides were determined by the method reported by Auerbach et al. 23 For MM-LDL inactivation studies, concentrated supernatants from HeLa-Tet-PON1 and HeLa-Tet-PON3 cell cultures were incubated with MM-LDL for 2 hours, filtered through 300 000 -molecular weight cutoff filters, and added to cultured confluent HAECs. Four hours later, the resulting supernatants were analyzed for monocyte chemotactic activity and lipid hydroperoxide content.
Results
Cloning and Expression of the Human PON3 Gene
As detailed in Methods, we RT-PCR-amplified and cloned a full-length cDNA encoding human PON3 from HepG2 cells (sequence submitted to GenBank, accession No. AF320003). A human tissue blot probed with PON3 cDNA identifies a band Ϸ1.3 kb in size (Figure 1 ). PON3 is expressed primarily in the liver, although low levels of PON3 message are also detected in the kidney (Figure 1 ). The PON3 antiserum identifies an Ϸ40-kDa protein in HepG2 cells (data not shown). Because low levels of PON3 message are also detected in the kidney (Figure 1) , we examined whether the 293 human embryonic kidney cell line expresses PON3 protein. The PON3 antiserum recognizes an Ϸ40-kDa protein in 293 cell culture supernatants (Figure 2 ), which can be competed away with PON3-specific peptides but not PON1-specific peptides (data not shown). Moreover, in these experiments, we do not detect any PON1 protein in 293 cell culture supernatants ( Figure 2 ). To determine whether PON3 is associated with human plasma fractions, Western analysis of HDL and LDL fractions was performed by using anti-PON1 and anti-PON3 antibodies. As expected, PON1 protein is detected in the HDL fractions of human plasma but not in the LDL fractions (Figure 2 ). PON3 protein is also detected only in the HDL fractions of human plasma (Figure 2 ). Our results suggest that (similar to PON1) PON3 protein is also a secreted protein associated with the HDL fractions of human plasma but absent in the LDL fractions.
PON3 Prevents the Formation of MM-LDL and Inactivates Preformed MM-LDL
We generated stable HeLa Tet On cell lines carrying doxycycline-inducible PON1 and PON3 cDNA. The resulting cell lines were designated HeLa-Tet-PON1 and HeLa-Tet-PON3, respectively. Parental HeLa Tet On cells do not express any detectable PON1 and PON3 mRNA or protein. PON1 and PON3 messages are induced by doxycycline in HeLa-Tet-PON1 and HeLa-Tet-PON3 cell lines, respectively ( Figure 3A) . Moreover, on induction with doxycycline, HeLa-Tet-PON1 and HeLa-Tet-PON3 cell lines synthesize PON1 and PON3 proteins, respectively ( Figure 3B ).
After incubation with HAECs, LDL is modified to become MM-LDL. The resulting MM-LDL is elevated in lipid hydroperoxide content and induces monocyte chemotactic activity in target HAECs. 3, 22 HDL and purified PON1 inhibit the modification of LDL by HAECs. 22 HAECs pretreated with concentrated (Ϸ10-fold) supernatants containing PON3 protein are less effective in modifying LDL (as measured by the induction of monocyte chemotactic activity) than are HAECs pretreated with concentrated supernatants from uninduced HeLa-Tet-PON3 cells ( Figure 4A ). This suggests that (similar to PON1) PON3 also prevents the modification of LDL by HAECs. Moreover, preformed MM-LDL incubated with supernatants containing PON3 protein has significantly lower amounts of lipid hydroperoxides ( Figure 4B , top) and is less effective in inducing monocyte chemotaxis ( Figure 4B , bottom).
PON3 Is Not Regulated by Oxidized Lipids
PON1 mRNA expression is repressed by ox-PAPC in HepG2 cells 24 and in the livers of mice fed an atherogenic diet. 25 We examined whether oxidized lipids can also regulate PON3 mRNA expression. PON3 message is constitutively expressed and, in contrast to PON1, is not affected by ox-PAPC in HepG2 cells ( Figure 5A ). Moreover, unlike PON1, PON3 mRNA is not altered in the livers of C57BL/6 mice fed an atherogenic diet ( Figure 5B and 5C ). Fourteen hours later, the resulting supernatants were collected and analyzed for MM-LDL formation (as measured by the ability to induce monocyte chemotactic activity as described in Methods). HPF indicates high-power field. B, PON3 inactivates preformed MM-LDL. HAECs were incubated with medium 199 alone (no addition), MM-LDL, or MM-LDL together with either purified PON1 (ϩpurified PON1), concentrated supernatants from doxycycline-induced HeLa-Tet-PON1 cells [ϩPON1 (ϩTet)], or concentrated supernatants from doxycycline-induced HeLa-Tet-PON3 cells [ϩPON3 (ϩTet)]. Two hours later, the resulting MM-LDL was reisolated by filtering through 300 000 -molecular weight cutoff filters and added to confluent HAEC cultures. Fourteen hours later, the resulting supernatants were tested for lipid hydroperoxide (LOOH) content by Auerbach assay (top of panel B) and the ability to induce monocyte chemotactic activity (bottom of panel B).
Figure 5. PON3 message is not regulated by oxidized lipids in
HepG2 cells or by a high-fat diet in mouse livers. A, Oxidized phospholipids do not regulate PON3 mRNA. HepG2 cells were either untreated (CON) or treated with PAPC or ox-PAPC for 24 hours. Total RNA was isolated and subjected to Northern analysis by use of human PON3 cDNA. B, PON1 message is repressed by a high-fat diet in the mouse liver. Livers from C57BL/6 mice on a chow diet or a high-fat diet for 15 weeks were harvested. Total RNA (20 g) was subjected to Northern analysis by use of mouse PON1 and GAPDH cDNA probes. Quantification was performed by phosphoimaging analysis, and ratios of PON1 to GAPDH were obtained. C, PON3 message is not regulated by a high-fat diet in the mouse liver. Total RNA (100 ng) from C57BL/6 mice on a chow diet or high-fat diet was subjected to RT-PCR analysis (20 cycles) by use of mouse PON3 and mouse GAPDH primers. The agarose gels were incubated in SYBR Green (Molecular Probes) for 30 minutes, washed, scanned with an FMBIOII scanner (Hitachi), and quantified.
Discussion Biochemical Properties and Biological Activities of PON1 and PON3 Proteins
Most of our understanding of PON proteins is derived primarily from studies involving PON1 protein. PON and arylesterase assays are routinely used to determine PON activity in human and animal serum samples. Although a physiological role for PON1 has not been proven, the ability of PON1 to prevent or destroy modifications in LDL is thought to be its prime biological activity in vivo. Interestingly, the arylesterase and PON activities of PON1 appear to be distinct from the ability of PON1 to protect against LDL oxidation, inasmuch as site-directed mutagenesis of the free sulfhydryl-modified Cys283 residue, although leaving its PON and arylesterase activities intact, eliminates its ability to protect LDL from oxidation. 26 However, this free-sulfhydryl group may still be important for the structure of the PON1 protein, inasmuch as chemical removal of this group abrogates its PON and arylesterase activities as well as its ability to protect against LDL oxidation. 26 Human PON3 protein shares the 3 conserved cysteine residues identified in PON1, suggesting that the free-sulfhydryl residue at Cys283 and the intramolecular disulfide bond linking the other 2 cysteines in PON1 may also be important features of the structure and in vivo activities PON3.
Recent studies attribute a new enzyme activity to PON1 and PON3 proteins. Kobayashi et al 27 have reported the cloning of a lactone hydrolase (lactonase) from Fusarium oxysporum AKU 3702 and discovered similarities between the lactonase and PON1 gene. While we were preparing the present article, Draganov et al 28 reported the purification and characterization of PON3 protein from rabbit serum. Interestingly, lactonase activity, as well as the lack of significant PON and arylesterase activities for rabbit PON3, facilitated the purification and characterization of rabbit serum PON3. 28 We did not test the supernatants from our PON3-overexpressing cell lines for lactonase activity. However, in agreement with Draganov et al, we did not find significant activity against the substrates paraoxon and phenyl acetate associated with PON3-containing supernatants (data not shown). However, because the PON and arylesterase activities of PON1 appear to be distinct from its in vivo ability to protect against LDL oxidation, 26 it is not surprising that the lack of apparent PON or arylesterase activity in PON3 does not preclude it from possessing the ability to protect LDL from oxidation. Indeed, like PON1, we find that PON3 is capable of preventing the formation of MM-LDL as well as inactivating preformed MM-LDL (Figure 4 ) but that it apparently lacks detectable arylesterase and PON activity. Draganov et al have shown that rabbit PON3 is also associated with the HDL fraction of rabbit serum and that rabbit PON3 is more effective than is rabbit PON1 in protecting LDL from copper-induced oxidation. 28 This suggests that in vivo, PON3 may play a significant atheroprotective role. It will be interesting to determine the exact spectrum of enzymatic products resulting from PON3 action on MM-LDL and whether PON1 and PON3 proteins possibly yield different enzymatic end products. We are currently preparing purified fractions of human PON3 to further characterize its enzymatic activities.
PON1 and PON3 proteins share numerous conserved phosphorylation and N-glycosylation consensus sites. However, it is not known whether the PON proteins are modified at these sites or whether modification at any of these sites is required for activity in vivo. Based on the sequence analysis, the predicted sizes for human PON1 and PON3 proteins are 38.6 and 39.6, respectively. However, HDL-associated PON1 runs as an Ϸ48-kDa protein, whereas PON3 runs as an Ϸ40-kDa protein. This suggests that PON1 may be significantly posttranslationally modified, especially relative to PON3.
Localization and Expression of PON3 Protein
We have found that PON3 (similar to PON1) is primarily localized to the HDL fractions of plasma and that the primary site of synthesis of the PON1 and PON3 proteins appears to be the liver. It is likely that PON1 and PON3 synthesis in the liver provides a location for the insertion of these proteins into nascent HDL particles. It will be interesting to determine whether the PON1 and PON3 proteins coexist on the same or different HDL particles. Interestingly, we detected significant amounts of PON3 mRNA in the kidney and also identified PON3 protein in the supernatants of 293 cell cultures; however, PON1 message is not detectable in the kidney (data not shown), and PON1 protein is not expressed in 293 cells (Figure 2 ). This suggests that PON3 protein may play a role, distinct from PON1, in the lipoprotein metabolism of the kidney.
Regulation of PON3 mRNA
PON1 mRNA expression is significantly repressed during an acute-phase response in rabbits, 29 in apoA-II transgenic mice, 30 in C57BL/6J(B6) mice fed an atherogenic diet, 25, 29 and in cultured HepG2 cells treated with the cytokines tumor necrosis factor and interleukin-1 31 or MM-LDL. 24 Because, unlike PON1, PON3 mRNA expression is not altered by either ox-PAPC in HepG2 cells ( Figure 5A ) or a high-fat diet in the livers of C57BL/6 mice ( Figure 5B and 5C ), PON1 and PON3 may play distinct roles in the prevention of atherosclerosis. PON3 may provide a basal constitutive atheroprotective function, whereas the protective effect of PON1 is more variable, inasmuch as PON1 expression is repressed by proatherogenic stimuli. Future studies, such as the generation of PON3 knockout and transgenic mouse models, may determine whether PON3 activity is required in vivo for the prevention of atherosclerotic lesion development.
In summary, PON3 is a secreted protein associated with HDL in the plasma and can participate in the prevention of LDL oxidation. These characteristics link PON3 with a group of enzymes, such as PON1, platelet-activating factor-acetyl hydrolase, and lecithin-cholesterol acyltransferase, which together may contribute to the antiatherogenic properties of HDL.
